CareDx (CDNA) Cash & Equivalents (2013 - 2026)

CareDx has reported Cash & Equivalents for 14 years, with the latest figure at $373.6 million in Q2 2026.

• Quarterly Cash & Equivalents rose 447.76% year-over-year to $373.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $373.6 million (up 447.76% YoY) and the FY2025 annual result came in at $65.4 million, down 42.95% from the prior year.
• Cash & Equivalents improved to $373.6 million in Q2 2026 per CDNA's latest filing, from $77.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $373.6 million in Q2 2026 and troughed at $65.4 million in Q4 2025.
• A 5-year average of $110.9 million and a median of $89.3 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents tumbled 76.5% in 2022, then surged 447.76% in 2026.
• Over 5 years, Cash & Equivalents stood at $89.9 million in 2022, then fell by 8.59% to $82.2 million in 2023, then surged by 39.53% to $114.7 million in 2024, then tumbled by 42.95% to $65.4 million in 2025, then surged by 471.06% to $373.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $373.6 million, $77.9 million, and $65.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.